Cervarix
Details for Cervarix vaccine and its components.
Sponsor:
GlaxoSmithKline Australia
Administration route:
Intramuscular injection
Vaccine group:
HPV vaccines
Registered for use in females aged 10 to <46 years.
2vHPV — Recombinant protein particulate (VLP) vaccine containing the major capsid (L1) protein of HPV types 16 and 18
Each 0.5 mL monodose vial or pre-filled syringe contains:
- 20 µg HPV-16 L1 protein
- 20 µg HPV-18 L1 protein
These are adjuvanted with AS04. The adjuvant comprises:
- 0.5 mg aluminium hydroxide
- 50 µg 3-O-desacyl-4’-monophosphoryl lipid A (MPL)
For full details, refer to the product information and consumer medicine information sheets for Cervarix vaccine available on the TGA website.
Page history
Last updated:
4 June 2018
Last reviewed:
4 June 2018
Definitions
- 2vHPV
- bivalent HPV vaccine
Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/vaccines/cervarix.